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Generation of non-viral, transgene-
free hepatocyte like cells with 
piggyBac transposon
Hokahiro Katayama1, Kentaro Yasuchika1, Yuya Miyauchi1, Hidenobu Kojima1, 
Ryoya Yamaoka1, Takayuki Kawai1, Elena Yukie Yoshitoshi1,2, Satoshi Ogiso1, Sadahiko Kita1, 
Katsutaro Yasuda1,2, Naoya Sasaki1, Ken Fukumitsu1, Junji Komori1, Takamichi Ishii1 & 
Shinji Uemoto1
Somatic cells can be reprogrammed to induced hepatocyte-like cells (iHeps) by overexpressing certain 
defined factors in direct reprogramming techniques. Of the various methods to deliver genes into 
cells, typically used genome-integrating viral vectors are associated with integration-related adverse 
events such as mutagenesis, whereas non-integrating viral vectors have low efficiency, making viral 
vectors unsuitable for clinical application. Therefore, we focused on developing a transposon system 
to establish a non-viral reprogramming method. Transposons are unique DNA elements that can be 
integrated into and removed from chromosomes. PiggyBac, a type of transposon, has high transduction 
efficiency and cargo capacity, and the integrated transgene can be precisely excised in the presence of 
transposase. This feature enables the piggyBac vector to achieve efficient transgene expression and a 
transgene-free state, thus making it a promising method for cell reprogramming. Here, we attempted 
to utilize the piggyBac transposon system to generate iHeps by integrating a transgene consisting of 
Hnf4a and Foxa3, and successfully obtained functional iHeps. We then demonstrated removal of the 
transgene to obtain transgene-free iHeps, which still maintained hepatocyte functions. This non-viral, 
transgene-free reprogramming method using the piggyBac vector may facilitate clinical applications of 
iHeps in upcoming cell therapy.
Therapy for lethal liver failure has mostly been limited to liver transplantation up to the present date, and the 
shortage of donor livers is a serious problem. Recently, cell transplantation is considered to be an alternative ther-
apeutic choice. Although the leading cell-source candidate should be hepatocytes, it remains difficult to establish 
stable procedures for their isolation, preservation, and supply1–4. To overcome this hurdle, hepatocyte-like cells 
generated from the patient’s own somatic cells are expected to be an attractive alternative. Experimental pro-
cedures have been reported for differentiation of other cell types into hepatocyte-like cells, such as mesenchy-
mal stem cells (MSCs)5–7, embryonic stem cells (ESCs)8,9, and induced pluripotent stem cells (iPSCs)10,11, under 
specific culture conditions. Since 2011, when Suzuki et al. and Huang et al. established a direct reprogramming 
technique to reprogram mouse fibroblasts to induced-hepatocyte like cells (iHeps) by overexpressing defined 
factors12,13, research in this field has proceeded rapidly.
Viral vectors have commonly been used as gene delivery tools because of their capability to transduce genes 
efficiently. However, although integrative vectors, such as retro- or lentivirus, have been utilized in many repro-
gramming trials for their strong ability to integrate and drive the expression of genes of interest, they present 
risks of genome mutagenesis and genotoxicity14,15 resulting from random genome integration. In contrast, 
non-integrative vectors, such as adenovirus, only provide transient gene expression and exhibit lower repro-
gramming effciency16,17. Therefore, given that viral vectors require special care in handling, non-viral vectors are 
preferable for generating clinically applicable iHeps.
Recently, non-viral methods to generate iHeps using synthetic mRNA18, microRNA19, or episomal vectors20 
have been reported; however, these methods have low reprogramming efficiency and the procedures are compli-
cated. In the present study, we focused on a piggyBac transposon system to establish a non-viral, transgene-free 
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reprogramming method. Transposons are unique DNA segments that were discovered in animals and plants 
as reversibly “mobile elements” in the genome21. In the presence of transposase, transposons are excised from 
a region on the host genome and integrated into another region of the genome. PiggyBac, a transposon discov-
ered in the cabbage looper moth Trichoplusia ni22, possesses a large cargo size and high transposition efficiency 
in mammalian cells23,24. Additionally, the excision of the transposon segment is precise and leaves no footprint 
on the host genome in which the transgene was integrated, thereby reducing the risk related to integration and 
making piggyBac a suitable vector for cell reprogramming25,26. In the present study, we attempted to generate 
iHeps from mouse MSCs by using piggyBac-based direct reprogramming to overexpress a transgene, and then 
removed the transgene to generate transgene-free iHeps. With this strategy, we successfully obtained functional 
transgene-free iHeps. This approach has the potential to advance iHep generation toward clinical application.
Results
Generating factor-integrated iHeps from mouse MSCs. First, we confirmed the maintenance of 
multipotency by differentiating the mouse MSCs into adipogenic and osteogenic lineages. The lipid droplets 
in adipocytes were visualized using Oil Red O staining and calcified osteocytes were visualized using Alizarin 
Red S staining (Fig. 1A). To construct the factor-expressing vector, we selected Hnf4a and Foxa3 as reprogram-
ming factors; Suzuki et al.12 selected these factors as one of the appropriate combinations to generate iHeps, and 
linked them with a 2A sequence to transcribe both genes equally. Then Hnf4a-2A-Foxa3 was inserted into the 
multi cloning site (MCS) of a dual-promoter piggyBac plasmid vector (pPBd), resulting in pPBHF3 (Fig. 1B). 
In pPBHF3, the CMV promoter was expected to drive Hnf4a and Foxa3 and the EF1a promoter to drive mRu-
by-puro, each present within a region of the transposon segment. pPBHF3 and pPBase were co-transfected into 
MSCs and the cells underwent the following protocol for iHep generation; additionally, pPBd and pPBase were 
co-transfected into MSCs as mock-transfected samples (pPBd-TCs) and the cells underwent the same steps. 
Consequently, the transgene integrated into pPBHF3-transfected cells contained Hnf4a, Foxa3 and mRuby-puro, 
whereas the transgene of pPBd-TCs contained only mRuby-puro.
From the day after transfection, antibiotic selection with puromycin at 5 μ g/ml was performed until 
post-transfection day 7. When the surviving cells reached confluence, all cells showed red fluorescence, suggest-
ing that they carried the integrated transgenes. Immunofluorescent staining detected the expression of Hnf4a 
and Foxa3 in the nuclei of surviving cells (Fig. 1C), indicating the successful activation of the transgenes in the 
pPBHF3-transfected cells.
Cell differentiation was initiated on post-transfection day 7, beginning with step A culture in expansion 
medium for 12 days followed by step B culture with maturation medium (Fig. 2A). 5′ -azacytidine was added for 
the first three days of differentiation step A. When expression of mRNA extracted every seven days was analyzed 
by quantitative PCR (qPCR), pPBd-TCs showed a slight but steady increase in albumin mRNA expression after 
Figure 1. Construction of expressing vector and transfection into MSCs. (A) The characteristics of 
MSCs-derived adipocytes and osteocytes were confirmed by Oil Red O staining and Arizarin Red S staining, 
respectively. (B) pPBd possesses transposon segment indicated between inverted terminal repeat sequences 
(ITR), carrying CMV promoter-MCS and EF1a promoter-mRuby-puro. A set of reprogramming factors, Hnf4a 
and Foxa3, were linked with T2A sequence and inserted into MCS to construct pPBHF3. (C) pPBHF3 and 
pPBase were co-transfected into MSCs. After antibiotics selection, all surviving cells expressed Hnf4a and Foxa3 
simultaneously. Scale bar : 100 um.
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post-transfection day 7, whereas pPBHF3-transfected cells showed a marked increase on day 7, with further 
increases thereafter (Fig. 2B). pPBHF3-transfected cells changed morphologically from a fibroblast-like shape to 
a polygonal shape and were densely proliferating (Fig. 2C). To evaluate reprogramming efficiency, immunofluo-
rescent staining for E-cadherin was performed for pPBHF3-transfected cells on day 15 of the differentiation step; 
cells were then observed and counted using microscopy (Supplementary Fig. S1). Of the first seeded 1.34 × 103 
cells per field, 336 ± 8.1 fluorescence-positive cells and colonies per field were detected; therefore, the reprogram-
ming ratio was estimated to be 25.1%. To evaluate the mRNA expression pattern, PCR products of cultured pPB-
HF3-transfected cells and pPBd-TCs, along with those of undifferentiated MSCs and adult mouse hepatocytes, 
were compared. In pPBHF3-transfected cells, representative markers typically seen in hepatocytes, such as Cdh1 
(E-cadherin), Alb, CK18, G6Pase, and Cyp3a11, were detected. Interestingly, Afp and CK19, which are hepatic 
progenitor markers and usually downregulated in hepatocytes, were also detected in pPBHF3-transfected cells 
(Fig. 2D). Thus, we considered that the pPBHF3-transfected cells had acquired hepatocyte characteristics and had 
been reprogrammed to iHeps.
Characterization of transgene-integrated iHeps. We next attempted to analyze the characteristics of 
these iHeps. To evaluate their proliferative capability, we passaged the cells at a 1:4 split ratio when they reached 
confluence. Although the time until confluence became gradually longer in iHeps than in pPBd-TCs and MSCs, 
iHeps still exhibited steady proliferation, even at passage 9 (Fig. 3A). When evaluating mRNA expression by 
qPCR, the levels of Cdh1, Alb, CK18, Ttr, Aat, G6P, Tat, Cyp2e1, and Cyp3a11 were elevated in iHeps as in hepat-
ocytes, and were higher than those in pPBd-TCs. Again, marked elevation of Afp and CK19 was observed in 
iHeps. Among fibroblast markers the level of Acta2 mRNA decreased, suggesting that transdifferentiation from 
mesenchymal to epithelial cells was taking place (Fig. 3B). To evaluate protein production ELISA was performed, 
revealing that secreted albumin was present in the culture medium of iHeps (Fig. 3C). We also evaluated urea 
production by measuring urea every 12 hours until 48 hours, and revealed significant increase in iHeps compared 
with PBd-TCs (Fig. 3D). Furthermore, immunofluorescent staining revealed the production of E-cadherin, albu-
min, and Cyp1a2 in iHeps (Fig. 3E). To assess mature hepatocyte function, Oil Red O staining revealed accumu-
lation of lipid droplets, periodic acid-Schiff (PAS) staining revealed storage of glycogen, and indocyanine-green 
Figure 2. Generation of factor-integrated iHeps. (A) Antibiotics selection proceeded until post-transfection 
day 7, followed by initiation of differentiation steps. The differentiation protocol was consisted of 2 steps. 
Components in each medium are shown. (B) Albumin mRNA expression of pPBHF3-transfected cells and 
mock-transfected cells (pPBd-TCs) from the day of vector transfection. Differentiation step was initiated on 
post-transfection day7. Data were normalized to MSCs on day 0. (C) The morphological change in pPBHF3-
transfected cells was observed on day 15 of differentiation step. All pPBHF3-transfected cells and pPBd-TCs 
expressed red fluorescence, indicating that transposon segments from pPBHF3 or pPBd were integrated, 
respectively. Scale bar: 100 um. (D) PCR bands of representative hepatic markers and hepatic progenitor 
markers are shown. Expression pattern of iHeps were similar to that of Hepatocytes but for Afp and CK19 
expression. iHeps and pPBd-TCs expressed bands specific to the transgene.
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Figure 3. Characteristics of factor-integrated iHeps. (A) Each type of cells were passaged at 1:4 split 
when they reach confluence, until passage 9. (B) mRNA expression level of hepatic, hepatic progenitor and 
mesenchymal markers were analyzed by quantitative PCR. Data were normalized to MSCs. *p < 0.05.  
(C) Albumin secretion from each cell types were evaluated by ELISA. *p < 0.05. (D) Urea production of 
transgene-integrated iHeps and pPB-TCs were measured every 12 hours. Data were normalized to the value at 
0 hour. *p < 0.05. (E) Immunofluorescent staining showed expression of albumin, E-cadherin and Cyp1a2 in 
iHeps. Scale bar: 100 um. (F) Storage of lipid droplets and glycogen inside the cells were evaluated by (a) Oil Red 
O staining and (b) PAS staining. (c) Uptake of ICG was evaluated. Scale bar: 100 um.
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(ICG) assay showed the capability for uptake of ICG in iHeps (Fig. 3F). These mature hepatocyte functions were 
not observed in pPBd-TCs or in undifferentiated MSCs.
Removal of the transposon and generation of transgene-free iHeps. To remove the transposon 
segment including the transgene, the iHeps were reseeded onto dishes and transfected with pPBase alone. As a 
result, when the cells proliferated and reached confluence, scattered fluorescence-negative colonies were observed 
(Fig. 4A). Then, the cells were dispersed and analyzed using FCM. The intensity of red fluorescence was attenu-
ated for the majority of the cells, compared to those that did not undergo pPBase transfection. An increase in the 
number of fluorescence-negative iHeps, for which the fluorescence intensity was under the threshold level, was 
observed (Fig. 4B), and these fluorescence-negative cells were sorted. pPBd-TCs underwent the same procedure. 
Sorted cells were then seeded onto a low-attachment 96-well plate to form spheroids (Fig. 4C). To confirm the 
removal of the transposon segment in these fluorescence-negative spheroidal iHeps and pPBd-TCs, PCR was per-
formed using a primer specific to the transposon region of pPBd; a negative result indicated that transgene-free 
spheroidal iHeps (TFSiHeps) and pPBd-TCs (TFSpPBd-TCs) had been obtained, respectively (Fig. 4D).
We then evaluated the mRNA expression level of albumin and Cyp3a11. When TFSiHeps were com-
pared with monolayer transgene-integrated iHeps, which were cultured on dishes and did not undergo the 
transgene-removal process, no significant difference was observed. However, when fluorescence-negative iHeps 
were seeded onto dishes, the monolayer transgene-free iHeps showed lower albumin and Cyp3a11 expression 
levels than both monolayer transgene-integrated iHeps and TFSiHeps (Fig. 5A). Therefore, we considered that 
the spheroidal form was better at maintaining the hepatocyte characteristics of transgene-free iHeps. To evaluate 
the mRNA expression pattern, PCR products of TFSiHeps and TFSpPBd-TCs, along with those of the spheroi-
dal undifferentiated MSCs and adult mouse hepatocytes, were compared. TFSiHeps expressed the representa-
tive markers Cdh1, Alb, CK18, G6Pase, Cyp3a11, AFP, and CK19 in the same pattern observed for monolayer 
transgene-integrated iHeps (Fig. 5B). To evaluate protein production ELISA was performed, revealing that 
secreted albumin was present in the culture medium of TFSiHeps (Fig. 5C). We also evaluated urea production 
by measuring urea every 12 hours until 48 hours, and revealed significant increase compared with TFSpPBd-TCs 
(Fig. 5D). Immunofluorescent staining revealed the production of E-cadherin, albumin, and Cyp1a2 in TFSiHeps 
(Fig. 5E). Additionally, PAS staining revealed the storage of glycogen in TFSiHeps (Fig. 5F).
Figure 4. Removal of transposon from transgene-integrated iHeps. (A) After the transfection of pPBase into 
iHeps, fluorescence-negative iHeps were observed (arrow). (B) Majority of the iHeps which underwent pPBase 
transfection showed a shift toward fluorescence attenuation. The population of cells under the threshold level 
(red line) increased, and they were sorted. (C) Fluorescent and bright field observation of iHeps and mock-
transfected cells (pPBd-TCs) in the form of spheroid, fluorescence(+ ) and (–), respectively. Scale bar: 300 um. 
(D) Removal of the transgene in fluorescence(–) spheroidal iHeps and pPBd-TCs were ascertained by lack of 
PCR bands with the primer specific to the transgene.
www.nature.com/scientificreports/
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Figure 5. Characteristics of spheroidal transgene-free iHeps. (A) Quantitative PCR analysis for mRNA 
expression of Alb and Cyp3a11. Monolayer-cultured transgene-integrated iHeps and transgene-free iHeps, and 
TFSiHeps were compared with each other. Data were normalized to monolayer-cultured pPBd-TCs. *p < 0.05. 
(B) PCR bands of representative markers are shown for MSCs, transgene-free pPBd-TCs, transgene-free 
iHeps (TFSiHeps) and hepatocytes, each in the form of spheroid. (C) Albumin secretion of each spheroidal 
cells were evaluated by ELISA. *p < 0.05. (D) Urea production of TFSiHeps and TFSpPB-TCs were measured 
every 12 hours. Data were normalized to the value at 0 hour. *p < 0.05. (E) Immunofluorescent staining showed 
expression of albumin, E-cadherin and Cyp1a2 in TFSiHeps. Scale bar: 50 um. (F) PAS staining showed glycogen 
storage in TFSiHeps. Scale bar: 100 um. (G) Quantitative PCR analysis for mRNA expression of Hnf4a, Foxa3 and 
other hepatocyte-specific genes. TFSiHeps which were cultured for 0, 6, 12 days after FCM were compared with 
monolayer-cultured transgene-integrated iHeps. Data were normalized to TFSpPBd-TCs. *p < 0.05. (H) Albumin 
secretion of TFSiHeps which were cultured for 0, 6, 12 days after FCM were evaluated by ELISA. *p < 0.05.
www.nature.com/scientificreports/
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Finally, we evaluated how these hepatic characteristics change after the transgene removal at mRNA and pro-
tein level. We performed qPCR for Hnf4a, Foxa3 and other representative hepatic markers as Alb, Cdh1, Cyp3a11, 
G6Pase and AFP (Fig. 5G), and also performed ELISA for measuring albumin (Fig. 5H) from TFSiHeps which 
were cultured for 0, 6, 12 days after FCM, respectively. After 12 days of culture, all genes still maintained higher 
expression level compared with TFSpPBd-TCs cultured for 12 days. Although a significant decrease of expression 
was observed in Foxa3 compared with transgene-integrated iHeps, no significant change was observed during 
the culture period, indicating that expression profile was maintained after spheroid formation. No significant 
difference was also observed in albumin secretion between the three time points.
These results suggest that even after transgene removal, TFSiHeps maintained the same level of hepatocyte 
function as monolayer transgene-integrated iHeps.
Discussion
iHeps are expected to be an alternative to hepatocytes in many situations27, such as a serving as a cell source for 
transplantation in severe liver dysfunction, in vitro disease modeling, pharmacokinetic analyses, and differen-
tiation or regeneration modeling in the hepatic lineage. In the initial reports on mouse iHeps, Suzuki et al.12 
transduced Hnf4a along with Foxa1, Foxa2, or Foxa3 as reprogramming factors into mouse fibroblasts using a 
retrovirus, and Huang et al.13 transduced Gata4, Hnf1a, and Foxa3 using a lentivirus. Both research groups con-
firmed that the iHeps acquired hepatic function and exhibited supportive effects on transplantation in a Fah−/− 
mouse model. Thereafter, various research groups successfully generated human fibroblast-derived iHeps28–31, 
and progress also occurred in the development of culture protocols and the search for suitable reprogramming 
factors. However, most studies on direct reprogramming utilize integrative viral vectors. These vectors carry 
in vitro risks such as insertional mutagenesis and genotoxicity14,15 as well as in vivo risks such as unexpected 
reactivation of the transgene and virus-related toxicity32,33. Therefore, a safer reprogramming vector is essential 
if iHep-related cell therapy is to be applied in human medicine in the future. The piggyBac transposon vector 
system used in this study is a non-viral vector that provides efficient integration. It has several advantages such as 
constant gene expression as well as retention of the transgene in the transfected cells even over long culture peri-
ods or repeated passages, which should enable antibiotic selection. Owing to its suitability for reprogramming, 
piggyBac has also been applied to generate iPSCs33–35 and has recently attracted attention as an effective vector for 
genetic engineering36.
To our knowledge, this is the first report to demonstrate iHep generation using piggyBac-based direct repro-
gramming. In this study, we showed that forced expression of an integrated transgene containing Hnf4a and Foxa3 
successfully reprogrammed MSCs into hepatocyte-like cells. The obtained iHeps exhibited hepatocyte-specific 
gene expression and protein production. The iHeps also exhibited hallmarks of mature hepatocyte function, such 
as lipid accumulation, glycogen storage, and ICG uptake. However, the maintenance of proliferative capability 
and expression of hepatic progenitor markers, such as AFP and CK19, suggest that the iHeps possess the charac-
teristics of premature hepatocytes as well.
MSCs have been investigated as a possible source of cells that can acquire hepatic characteristics when cul-
tured in specific conditions5; therefore, we speculated that they would be appropriate for generating iHeps by 
direct reprogramming. In the present study, MSCs without overexpression of reprogramming factors were treated 
as mock-transfected cells and exhibited limited expression of hepatocyte-specific genes; additionally, they did not 
exhibit any function of maturated hepatocytes in this differentiation protocol, even in the form of spheroids. In 
contrast, when reprogramming factors were overexpressed in MSCs, they manifested mature hepatocyte func-
tion, indicating that efficient reprogramming was achieved.
We also demonstrated that fluorescence-negative iHeps, which were confirmed to be transgene-free iHeps, still 
exhibited hepatocyte function in spheroidal form comparable to that of transgene-integrated iHeps. Moreover, 
we showed that hepatic profile of transgene-free iHeps was maintained in the form of spheroid. Although the 
expression of Foxa3 decreased as expected after the exogenous expression was lost, Hnf4a did not show significant 
decrease. The persistent endogenous expression of Hnf4a is considered to be one of the reasons for maintaining 
hepatocyte function, because Hnf4a plays a central role for the maintenance of hepatocyte differentiation37,38.
It is also suspected that the reprogrammed cells that underwent gene removal and FCM processes were sus-
ceptible to a decrease of viability and acquired hepatocyte function, whereas the cell-cell interactions in the sphe-
roidal iHeps supported the maintenance of viability and promotion of differentiation into hepatocytes39–41. Thus, 
3D culture environments including spheroids are expected to contribute to the maintenance and maturation 
of iHeps as reported for MSCs, iPSCs, and ESCs42–44, which could be an interesting avenue for future research. 
Although the present study utilized a simple model with 2 reprogramming factors, other factor combinations 
can also be used in the piggyBac system to achieve iHeps with higher levels of hepatocyte functions; as many as 6 
factors have been reported4 (HNF1A, HNF4A, HNF6, ATF5, PROX1, and CEBPA).
Because risk-reduced transgene-free iHeps are expected to be useful for achieving therapeutic effects against 
liver disorder, studies to transplant these iHeps into the liver disorder models are desirable. In general, a large 
number of cells are required for cell transplantation, but cells do not proliferate in spheroidal form, which makes 
it difficult for the present model to supply abundant iHeps for cell transplantation. To overcome this problem, 
exploration of culture conditions that support the proliferation of transgene-free iHeps while maintaining hepat-
ocyte functions is necessary. For example, the above mentioned 3D culture environment could serve as an alter-
native to spheroids, and progress in cell culture techniques with small compounds or cytokines may further 
support such efforts.
In conclusion, we suggest that the piggyBac-mediated method is a novel and promising approach to generate 
non-viral, transgene-free iHeps. Further advancement in achieving higher function and optimal culture condi-
tions will facilitate the application of iHeps for upcoming cell therapies against severe liver dysfunction.
www.nature.com/scientificreports/
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Methods
Preparing MSCs. C57BL/6 mouse bone marrow-derived mesenchymal stem cells (MSCs), passage 6, 
were purchased from Cyagen Biosciences. MSCs were seeded and expanded on collagen 1-coated dishes (AGC 
TECHNO GLASS) in DMEM containing 10% FBS (Invitrogen) and 1% penicillin/streptomycin (Invitrogen). 
MSCs of passage 8–9 were used for experiments.
MSCs underwent adipogenic and osteogenic differentiation steps using differentiation kits (Cyagen) and the 
protocol was carried out according to the manufacturer’s instructions. In brief, for adipogenesis, adipogenic dif-
ferentiation medium was fed for three days, followed by MSC maintenance medium for a day, and repeat this 
process for three times. Then cells were cultured in MSC maintenance medium for seven days. Differentiated 
cells were evaluated by Oil Red O staining. For osteogenesis, cells were cultured in osteogenic differentiation 
medium for three weeks and observed after Arizarin Red S staining. MSCs were certified to exhibit a cell surface 
marker pattern positive for CD29, CD44, CD31 and Sca-1 and negative for CD117 by flow cytometry (FCM) by 
manufacturer.
Vector construction. PiggyBac dual promotor transposon vector (pPBd) along with piggyBac transposase 
expressing vector (pPBase) were purchased from System Biosciences. pPBd has multi-cloning site (MCS) down 
stream of CMV promotor, and mRuby and puro down stream of EF1a promotor.
Hnf4a and Foxa3 cDNA were obtained from mouse total mRNA by reverse transcription PCR. Then both of 
them were linked together via T2A sequence by recombinant PCR to construct Hnf4a-2A-Foxa3 segment, adding 
Xba1 and BamH1 sequence on each end. This segment was inserted into Xba1/BamH1 restriction site among 
MCS of pPBd by digestion and ligation, resulting in pPB-Hnf4a-2A-Foxa3-mRubyPuro (pPBHF3).
Cell culture/generation of transgene-integrated iHeps. pPBHF3 and pPBase were co-transfected 
into MSCs with Lipofectamine 3000 (Invitrogen). pPBd and pPBase were transfected into MSCs in the same 
manner as mock samples (pPBd-TCs). After medium was changed, puromycin was added for antibiotic selection 
and when cells reached confluent the differentiation step was initiated.
For the first twelve days, as step A, cells were cultured in expansion Medium consisted of DMEM/F-12 
(Invitrogen) containing 10% fetal bovine serum (FBS) (Invitrogen), 1% penicillin/streptomycin (Wako), 10 mM 
nicotinamide (Sigma Aldrich), 100 μ M 2-melcaptomethanol (Wako), 100 μ M ascorbic acid (Wako), 1 μ M 
Dexamethasone (Dex) (Wako) and ITS (BD Biosciences), supplemented with 20 ng/ml hepatocyte growth factor 
(HGF) (R&D Systems) and 20 ng/ml epidermal growth factor (EGF) (R&D systems). Then step B was initiated 
with maturation medium consisted of IMEM + GlutaMax (Invitrogen) containing 0.5% bovine serum albumin 
(BSA) (Wako), 1% penicillin/streptomycin, 10 mM nicotinamide, 100 μ M 2-melcaptomethanol, 500 μ M ascorbic 
acid, 1 μ M Dex and ITS, supplemented with 20 ng/ml oncostatin M (OSM) (R&D Systems) and 20 ng/ml EGF. 
For the first three days of the differentiation step, 200 uM 5′ -azacytidine (5′ -aza) was added to expansion medium.
Generation of transgene-free iHeps. pPBase alone were transfected into iHeps with ViaFect (Promega) 
and cells were expanded until confluence for a few days. Then iHeps which were negative for red fluorescence were 
sorted by FCM, detected in PE-Texas Red filter. We prepared cells as described previously. The threshold level for 
red fluorescence positive was determined as the level under which less than 0.05% of the transgene-integrated 
cells, which did not undergo transgene-removal process, remained. Sorted cells were reseeded onto low attach-
ment 96well V bottom plate (SUMILON) at 1 × 104 cells per well to form spheroids. After 1 week of culture, 
TFSiHeps along with TFSpPBd-TCs were collected for mRNA extraction, staining and ELISA, and culture 
medium for urea measurements. The image of whole protocol is depicted in Supplementary Fig. S2.
Primary hepatocyte isolation and culture. Adult C57BL/6 mice were subjected to two-step colla-
genase perfusion for isolation of primary hepatocytes as described previously4,45. Briefly, after laparotomy portal 
veins were cannulated with 25-gauge needles. Through these needles, the livers were preperfused with 10 ml 
Hanks-EGTA. Subsequently, the livers were perfused with 15 ml collagenase solution containing 0.3% dispase 
II (Sanko Junyaku) and 0.3% collagenase II (Gibco). Then the livers were minced with a scissor and filtered 
thorough 50 N polypropylene mesh, and the suspension was centrifuged two times at 50 g for 4 min. Cell pellets 
were resuspended and cultured with HBM (Lonza) onto collagen 1-coated dish for two days for RNA extraction 
or other experiments. For spheroid formation cells were seeded into 96well V bottom plate and cultured for four 
days until analyses.
PCR/Quantitative PCR. PCR and RT-PCR assays were performed as previously described46–48. Total RNA 
was extracted with PureLink RNA mini kit (Thermo Fischer Scientific) and then reverse-transcribed into cDNA 
with Revertra Ace (Toyobo). qPCR was performed with Power SYBR Green (Applied Biosystems). The quantifi-
cation of the expression of genes were evaluated as the relative level normalized to endogenous Actin beta. Primer 
sequences for PCR analyses are listed in Supplementary Table S1.
Immunofluorescent staining. The cultured cells were fixed and stained as previously described49. Primary 
antibodies were as follows; mouse anti-human Hnf4a (PPMX), goat anti-human Foxa3 (Santa Cruz), goat 
anti-mouse albumin antibody (Bethyl Laboratories), mouse anti-mouse E-cadherin (Abcam), mouse anti-mouse 
cytchromeP450 1A2 (Abcam) at 1:200 respectively. The sections were incubated for two hours with second-
ary antibodies; Alexa 488-conjugated rabbit anti-goat IgG or goat anti-mouse IgG at 1:1000. After washing, the 
stained sections were covered with Vectashield mounting medium with DAPI (Vector Laboratories).
Spheroids were first embedded in iPGel (NIPPON Genetics) and fixed with 4% PFA overnight, then embedded 
in paraffin and cut in 5 μ m thick. After deparaffinization and antigen retrieval using a Target Retrieval Solution 
(Dako), nonspecific binding was blocked with 1% bovine serum albumin (Sigma Aldrich) dissolved in 0.1% 
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Polyoxyethylene Octylphenyl Ether (Wako) in PBS. The primary and secondary antibodies reactions were carried 
out in the same way for cultured cells.
Measurements of albumin and urea. Cells on 35 mm collagen1-coated dishes and spheroids in 96 well 
plate were incubated in newly fed maturation medium, and culture supernatants were collected. For albumin 
measurement, culture medium for 24 hour was collected. The quantity of albumin was calculated using mouse 
albumin ELISA kit (Bethyl Labolatories) and urea using QuantiChrom Urea Assay Kit (BioAssay Systems), each 
according to the manufacturer’s instructions.
Oil Red O staining, Periodic Acid-Schiff (PAS) staining, ICG uptake assay. For Oil Red O staining, 
linoleic acid (Wako) was added into the medium at 10 mg/ml and incubated for 30 minutes. After washed with 
PBS, cells were fixed with 4% PFA at room temperature for 30 minutes and washed with 60% isopropanol, fol-
lowed by incubation for 30 minutes with Oil Red solution which Oil Red powder (Sigma Aldrich) was dissolved 
into isopropanol and diluted to 60% with distilled water. Then cells were washed with distilled water three times. 
For PAS staining, cultured cells were stained by periodic acid-Schiff (MUTO PURE CHEMICALS) following the 
manufacturer’s instructions. For paraffin-embedded spheroids, the same procedure was carried out after depa-
raffinization. For ICG uptake assay, indocyanine green (Wako) was added in the medium at 0.1 mg/ml and incu-
bated for 1 hour, followed by washing with PBS three times.
Statistics. The results are expressed as mean ± SEM. Statistical significance was assessed using unpaired 
t-test; p-values < 0.05 were considered statistically significant. Data analysis was performed by GraphPad Prism. 
For all statistics, data from at least three independent samples were used.
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